• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.

作者信息

Guy Holly, Walder Lydia, Fisher Mark

机构信息

FIECON Ltd, 3 College Yard, Lower Dagnall Street, St Albans, Hertfordshire, AL3 4PA, UK.

出版信息

Pharmacoeconomics. 2019 Jul;37(7):965-967. doi: 10.1007/s40273-019-00803-7.

DOI:10.1007/s40273-019-00803-7
PMID:31044349
Abstract
摘要

相似文献

1
Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.对《关于“尼拉帕利与常规监测、奥拉帕利和卢卡帕利在美国卵巢癌患者维持治疗中的成本效益”的评论》的回应
Pharmacoeconomics. 2019 Jul;37(7):965-967. doi: 10.1007/s40273-019-00803-7.
2
Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".关于《尼拉帕利与常规监测、奥拉帕利和卢卡帕利在美国卵巢癌患者维持治疗中的成本效益》的评论
Pharmacoeconomics. 2019 Aug;37(8):1065-1067. doi: 10.1007/s40273-019-00815-3.
3
Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".关于“在美国，尼拉帕利与常规监测、奥拉帕利和卢卡帕利用于卵巢癌患者维持治疗的成本效益”的评论
Pharmacoeconomics. 2019 Jul;37(7):963-964. doi: 10.1007/s40273-019-00802-8.
4
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.尼拉帕利对比常规监测、奥拉帕利和鲁卡帕利用于美国卵巢癌维持治疗的成本效益研究。
Pharmacoeconomics. 2019 Mar;37(3):391-405. doi: 10.1007/s40273-018-0745-z.
5
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.奥拉帕利和尼拉帕利作为复发性铂敏感卵巢癌维持治疗的成本效果分析。
Expert Rev Pharmacoecon Outcomes Res. 2022 Apr;22(3):489-496. doi: 10.1080/14737167.2021.1954506. Epub 2021 Aug 6.
6
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.三种PARP抑制剂（奥拉帕利、尼拉帕利和鲁卡帕利）作为铂类治疗反应良好的卵巢癌患者维持治疗的间接比较。
Int J Clin Pharmacol Ther. 2022 Aug;60(8):370-372. doi: 10.5414/CP204243.
7
Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.尼拉帕利作为基于铂类化疗后的复发性卵巢癌维持治疗的预算影响。
J Comp Eff Res. 2019 Jun;8(8):577-587. doi: 10.2217/cer-2018-0069. Epub 2019 Apr 2.
8
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.尼拉帕利和奥拉帕利用于美国铂敏感复发性卵巢癌维持治疗的预算影响分析
J Med Econ. 2019 Feb;22(2):187-195. doi: 10.1080/13696998.2018.1557199. Epub 2019 Jan 4.
9
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.PARP 抑制剂维持治疗铂敏感复发性卵巢癌患者的成本效果分析。
Gynecol Oncol. 2015 Oct;139(1):59-62. doi: 10.1016/j.ygyno.2015.08.013. Epub 2015 Aug 22.
10
[Cancer therapy by PARP inhibitors].[聚（ADP-核糖）聚合酶抑制剂用于癌症治疗]
Nihon Rinsho. 2015 Aug;73(8):1330-5.

引用本文的文献

1
Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States.聚（ADP-核糖）聚合酶（PARP）抑制剂奥拉帕利在中国和美国转移性去势抵抗性前列腺癌患者中的成本效益
Ann Transl Med. 2022 Aug;10(15):830. doi: 10.21037/atm-22-3637.
2
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.聚（ADP-核糖）聚合酶抑制剂治疗的乳腺癌和卵巢癌患者不良事件管理的成本比较：基于3期临床试验的分析
J Mark Access Health Policy. 2022 Jun 8;10(1):2078474. doi: 10.1080/20016689.2022.2078474. eCollection 2022.

本文引用的文献

1
Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".关于“在美国，尼拉帕利与常规监测、奥拉帕利和卢卡帕利用于卵巢癌患者维持治疗的成本效益”的评论
Pharmacoeconomics. 2019 Jul;37(7):963-964. doi: 10.1007/s40273-019-00802-8.
2
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.尼拉帕利对比常规监测、奥拉帕利和鲁卡帕利用于美国卵巢癌维持治疗的成本效益研究。
Pharmacoeconomics. 2019 Mar;37(3):391-405. doi: 10.1007/s40273-018-0745-z.
3
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
奥拉帕利单药维持治疗铂敏感复发性浆液性卵巢癌患者的总生存期：一项随机、安慰剂对照、双盲、2 期临床试验的更新分析。
Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
4
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.奥拉帕利维持治疗铂类敏感复发性卵巢浆液性癌患者：随机 2 期试验中 BRCA 状态的预设回顾性分析结果
Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.